Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiac ablation firm pulls in $5m series B

This article was originally published in Clinica

Executive Summary

Advanced Cardiac Therapeutics (ACT) is preparing to initiate full European commercial launch of its cardiac ablation technology this year, after closing a $5m series B financing round. NBGI Ventures was the lead investor. ACT has developed an irrigated, radiofrequency cardiac ablation catheter, which incorporates a microwave radiometry technology that measures – in real time – ablation temperatures inside cardiac tissue. This gives the electrophysiologist better control when they are creating lesions with the ablation catheter, and potentially improves patient outcomes, says Laguna Beach, California-based ACT. Current irrigated cardiac ablation systems do not provide tissue temperature feedback, according to the firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel